Confidentiality Agreement

The undersigned reader acknowledges that the information provided by _______________ in this
business plan is confidential; therefore, reader agrees not to disclose it without the express written
permission of _______________.
It is acknowledged by reader that information to be furnished in this business plan is in all respects
confidential in nature, other than information which is in the public domain through other means and
that any disclosure or use of same by reader, may cause serious harm or damage to
_______________.
Upon request, this document is to be immediately returned to _______________.
___________________
Signature
___________________
Name (typed or printed)
___________________
Date
This is a business plan. It does not imply an offering of securities.

Table of Contents
1.0 Executive Summary ......................................................................................................................................1
Chart: Highlights ..............................................................................................................................1
1.1 Objectives ...........................................................................................................................................1
1.2 Mission ................................................................................................................................................1
1.3 Keys to Success..................................................................................................................................1
2.0 Company Summary ......................................................................................................................................2
2.1 Company Ownership ..........................................................................................................................2
2.2 Start-up Summary ...............................................................................................................................2
Table: Start-up.................................................................................................................................2
Chart: Start-up .................................................................................................................................3
3.0 Products ........................................................................................................................................................3
4.0 Market Analysis Summary ............................................................................................................................3
4.1 Market Segmentation ..........................................................................................................................3
Table: Market Analysis ....................................................................................................................4
Chart: Market Analysis (Pie) ...........................................................................................................4
4.2 Target Market Segment Strategy .......................................................................................................4
4.3 Industry Analysis .................................................................................................................................4
4.3.1 Competition and Buying Patterns ..........................................................................................4
5.0 Strategy and Implementation Summary .......................................................................................................5
5.1 SWOT Analysis ...................................................................................................................................5
5.1.1 Strengths ................................................................................................................................5
5.1.2 Weaknesses ..........................................................................................................................5
5.1.3 Opportunities ..........................................................................................................................5
5.1.4 Threats ...................................................................................................................................5
5.2 Competitive Edge................................................................................................................................5
5.3 Marketing Strategy ..............................................................................................................................5
5.4 Sales Strategy .....................................................................................................................................6
5.4.1 Sales Forecast .......................................................................................................................6
Table: Sales Forecast ...........................................................................................................6
Chart: Sales Monthly .............................................................................................................6
Chart: Sales by Year .............................................................................................................7
5.5 Milestones ...........................................................................................................................................7
Table: Milestones ............................................................................................................................7
Chart: Milestones ............................................................................................................................8
6.0 Management Summary ................................................................................................................................8
6.1 Personnel Plan ....................................................................................................................................9
Table: Personnel .............................................................................................................................9
7.0 Financial Plan ...............................................................................................................................................9
7.1 Start-up Funding .................................................................................................................................9
Table: Start-up Funding ................................................................................................................10
7.2 Important Assumptions .....................................................................................................................10
7.3 Break-even Analysis .........................................................................................................................10
Table: Break-even Analysis ..........................................................................................................10
Chart: Break-even Analysis ...........................................................................................................11
7.4 Projected Profit and Loss ..................................................................................................................11
Table: Profit and Loss ...................................................................................................................12
Chart: Profit Monthly .....................................................................................................................12
Chart: Profit Yearly ........................................................................................................................13
Chart: Gross Margin Monthly ........................................................................................................13
Chart: Gross Margin Yearly...........................................................................................................14
7.5 Projected Cash Flow .........................................................................................................................14
Table: Cash Flow ..........................................................................................................................15
Chart: Cash ...................................................................................................................................16
Page 1

Table of Contents
7.6 Projected Balance Sheet ..................................................................................................................16
Table: Balance Sheet ....................................................................................................................17
7.7 Business Ratios ................................................................................................................................17
Table: Ratios .................................................................................................................................18
Table: Sales Forecast .........................................................................................................................................1
Table: Personnel .................................................................................................................................................2
Table: Profit and Loss .........................................................................................................................................3
Table: Cash Flow ................................................................................................................................................4
Table: Balance Sheet .........................................................................................................................................5

Page 2

ASCLEP PHARMA
1.0 Executive Summary

1.1 Objectives
1.

To deliver the medicines and surgical supplies to the retailers such us hospitals , clinics
and medical shops .
2. To establish ourself as a premier pharmaceutical distributing company by 2020

1.2 Mission
ASCLEP Pharma offers pharmaceutical , biotechnological and medical device manufactures a
reliable , high quality alternative way for sales and marketing of the products. ASCLEP pharma
improves the return on sales and marketing investment by accelerating the physician learning curve
on prelaunch, new, and existing products. In addition,ASCLEP will benefit small and innovative
biotechnology and pharmaceutical companies that do not have an extensive sales force to cover
Kerala especially in southern districts like Trivandrum, Kollam,Pathanamthitta. Alappuzha &
Kottayam.
1.3 Keys to Success
Page 1

ASCLEP PHARMA

2.0 Company Summary

ASCLEP Pharma is a pharamaceutical Distribution Company which is providing high level expertise
in the marketing and selling of pharmaceutical products. The company's headquarters is in
Pathanamthitta Kerala India

2.1 Company Ownership

ASCLEP Pharma is under mutual partnership of

1.
2.
3.
4.

Dr Hassan Mohammed Aziz

Mr Arun Kumar MJ
Mr Shameer A
Mr Fayush Yonus

Each of the share holders holds 25% of shares of the company and the profit share of each share
holder is 25% of total net profit.

2.2 Start-up Summary

The table below illustrates a complete breakdown of all start-up assets that are needed, as total
start-up requirements. Currently, we have no short-term liabilities.

Table: Start-up
Start-up
Requirements
Start-up Expenses
Legal
Stationery
Insurance
Rent
Other
Total Start-up Expenses

$30,000
$5,000
$10,000
$10,000
$10,000
$65,000

Start-up Assets
Cash Required
Start-up Inventory
Other Current Assets
Long-term Assets
Total Assets

$100,000
$200,000
$0
$0
$300,000

Total Requirements

$365,000

Page 2

ASCLEP PHARMA

3.0 Products
The products that ASCLEP Pharma offers
1.
2.
3.

Medicines
Medical Equipments
Surgical Instruments

4.0 Market Analysis Summary

Currently, the largest market segment is the pharmaceutical industry. We have a huge opportunity
in this segment. ASCLEP Pharma is fully concenterated in Hospitals Clinics and Medical shops in
southern districts of Kerala such as Pathanamthitta , Kollam, Thiruvananthapuram , Alappuzha &
Kottayam in the first two years and we will extend the demographics regions such
as Ernakulam , Thrissur, Koazhikode & Malappuram .
Before 2020 we will acquire the distribution for all demographics regions of the Kerala.

4.1 Market Segmentation

Conduct the Market Study??????????????????????????????????

Page 3

ASCLEP PHARMA
Table: Market Analysis
Market Analysis
Potential Customers
Hospitals
Clinics
Medical Shops
Total

Year 1

Year 2

Year 3

Year 4

Year 5

20
25
100
145

30
38
150
218

45
57
225
327

68
86
338
492

102
129
507
738

Growth
50%
50%
50%
50.20%

CAGR
50.28%
50.72%
50.06%
50.20%

4.2 Target Market Segment Strategy

Conduct Study ....................Discuss with Partners
Dr Hassan 's PART

4.3 Industry Analysis

To be analysed......................................

4.3.1 Competition and Buying Patterns

Buying Patterns ......Competitions ..................To Be Analaysed .....

Primary data
Pathanamthitta
Page 4

ASCLEP PHARMA
1.
2.
3.
4.
5.

MALANADU PHARMACEUTICALS
Kozhencherry, Pathanamthitta
M/S Suraj Pharma
Thiruvalla, Pathanamthitta
Samsons
Kozhencherry, Pathanamthitta
Pharma Traders
Thiruvalla, Pathanamthitta
M M Drug Links
Thiruvalla, Pathanamthitta

5.0 Strategy and Implementation Summary

5.1 SWOT Analysis

Have a chat with partners..................

5.1.1 Strengths
Have a chat with partners..................

5.1.2 Weaknesses
Have a chat with partners..................

5.1.3 Opportunities
Have a chat with partners..................

5.1.4 Threats
Have a chat with partners..................

5.2 Competitive Edge

Have a chat with partners..................

5.3 Marketing Strategy

Have a chat with partners..................
Have a chat with partners..................

Page 5

ASCLEP PHARMA
5.4 Sales Strategy
To be Checked with Hassan ..................

5.4.1 Sales Forecast

Table: Sales Forecast

Sales Forecast
Year 1

Year 2

Year 3

Sales
Medicines
Surgical Instruments
Total Sales

$300,000
$300,000
$600,000

$450,000
$450,000
$900,000

$600,000
$600,000
$1,200,000

Direct Cost of Sales

Cost of Goods Medicines
Cost of Goods Surgical Supplies
Transportation Costs
Subtotal Direct Cost of Sales

Year 1
$180,000
$180,000
$60,000
$420,000

Year 2
$270,000
$270,000
$90,000
$630,000

Year 3
$405,000
$405,000
$120,000
$930,000

Page 6

ASCLEP PHARMA

5.5 Milestones
Have a chat with partners..................

Table: Milestones
Milestones
Milestone
Name me
Name me
Name me
Name me
Name me
Name me
Name me
Name me
Name me
Name me
Totals

Start Date
5/8/2015
5/8/2015
5/8/2015
5/8/2015
5/8/2015
5/8/2015
5/8/2015
5/8/2015
5/8/2015
5/8/2015

End Date
6/7/2015
6/7/2015
6/7/2015
6/7/2015
6/7/2015
6/7/2015
6/7/2015
6/7/2015
6/7/2015
6/7/2015

Budget
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0

Manager
ABC
ABC
ABC
ABC
ABC
ABC
ABC
ABC
ABC
ABC

Department
Department
Department
Department
Department
Department
Department
Department
Department
Department
Department

Page 7

ASCLEP PHARMA

6.0 Management Summary

ASCLEP Pharma is a Parnership firm formed by 4 partners who are excelled in four different
segments.

1 DR Hassan Mohammed Aziz MBBS

Chairman of the company who is a graduate in medical science , practicing as a Junior Doctor in
various hospitals. He posses the Head of Marketing department of the company

2 Mr Fayush Yonus MBA

Managing Director of the company who is graduated in human resourse and marketing, worked
as Administration Manager in UAE and as credit officer in Standard Chartered Bank India.
3 Mr Arun Kumar MJ BCom
Head of Finance Department of the company,who have an immense experience in accounting and
banking sector ,wo
4 Mr Shameer A NeBosh
Head of HR department , who have an immense experience in EMAAR Group ,Dubai ,UAE

Page 8

ASCLEP PHARMA
6.1 Personnel Plan

Table: Personnel
Personnel Plan
HR Department
Finanace Department
Marketing Department
Total People
Total Payroll

Year 1
$0
$0
$0
0

Year 2
$0
$0
$0
0

Year 3
$0
$0
$0
0

$0

$0

$0

7.0 Financial Plan

7.1 Start-up Funding

Page 9

ASCLEP PHARMA
Table: Start-up Funding
Start-up Funding
Start-up Expenses to Fund
Start-up Assets to Fund
Total Funding Required

$65,000
$300,000
$365,000

Assets
Non-cash Assets from Start-up
Cash Requirements from Start-up
Additional Cash Raised
Cash Balance on Starting Date
Total Assets

$200,000
$100,000
$0
$100,000
$300,000

Liabilities and Capital

Liabilities
Current Borrowing
Long-term Liabilities
Accounts Payable (Outstanding Bills)
Other Current Liabilities (interest-free)
Total Liabilities

$0
$0
$0
$0
$0

Capital
Planned Investment
Owner
Investor
Additional Investment Requirement
Total Planned Investment

$0
$0
$365,000
$365,000

Loss at Start-up (Start-up Expenses)

Total Capital

($65,000)
$300,000

Total Capital and Liabilities

$300,000

Total Funding

$365,000

7.2 Important Assumptions

7.3 Break-even Analysis

Table: Break-even Analysis

Break-even Analysis
Monthly Revenue Break-even
Assumptions:
Average Percent Variable Cost
Estimated Monthly Fixed Cost

$0

70%
$0

Page 10

ASCLEP PHARMA

7.4 Projected Profit and Loss

Page 11

ASCLEP PHARMA
Table: Profit and Loss
Pro Forma Profit and Loss
Sales
Direct Cost of Sales
Other Costs of Sales
Total Cost of Sales

Year 1
$600,000
$420,000
$0
$420,000

Year 2
$900,000
$630,000
$0
$630,000

Year 3
$1,200,000
$930,000
$0
$930,000

Gross Margin
Gross Margin %

$180,000
30.00%

$270,000
30.00%

$270,000
22.50%

Expenses
Payroll
Marketing/Promotion
Depreciation
Rent
Utilities
Insurance
Payroll Taxes
Other

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

Total Operating Expenses

$0

$0

$0

Profit Before Interest and Taxes

EBITDA
Interest Expense
Taxes Incurred

$180,000
$180,000
$0
$54,000

$270,000
$270,000
$0
$81,000

$270,000
$270,000
$0
$81,000

Net Profit
Net Profit/Sales

$126,000
21.00%

$189,000
21.00%

$189,000
15.75%

Page 12

ASCLEP PHARMA

Page 13

ASCLEP PHARMA

7.5 Projected Cash Flow

Page 14

ASCLEP PHARMA
Table: Cash Flow
Pro Forma Cash Flow
Year 1

Year 2

Year 3

Cash from Operations

Cash Sales
Subtotal Cash from Operations

$600,000
$600,000

$900,000
$900,000

$1,200,000
$1,200,000

Additional Cash Received

Sales Tax, VAT, HST/GST Received
New Current Borrowing
New Other Liabilities (interest-free)
New Long-term Liabilities
Sales of Other Current Assets
Sales of Long-term Assets
New Investment Received
Subtotal Cash Received

$0
$0
$0
$0
$0
$0
$0
$600,000

$0
$0
$0
$0
$0
$0
$0
$900,000

$0
$0
$0
$0
$0
$0
$0
$1,200,000

Year 1

Year 2

Year 3

Expenditures from Operations

Cash Spending
Bill Payments
Subtotal Spent on Operations

$0
$349,650
$349,650

$0
$784,831
$784,831

$0
$1,088,958
$1,088,958

Additional Cash Spent

Sales Tax, VAT, HST/GST Paid Out
Principal Repayment of Current Borrowing
Other Liabilities Principal Repayment
Long-term Liabilities Principal Repayment
Purchase Other Current Assets
Purchase Long-term Assets
Dividends
Subtotal Cash Spent

$0
$0
$0
$0
$0
$0
$0
$349,650

$0
$0
$0
$0
$0
$0
$0
$784,831

$0
$0
$0
$0
$0
$0
$0
$1,088,958

Net Cash Flow

Cash Balance

$250,350
$350,350

$115,169
$465,519

$111,042
$576,561

Cash Received

Expenditures

Page 15

ASCLEP PHARMA

7.6 Projected Balance Sheet

Page 16

ASCLEP PHARMA
Table: Balance Sheet
Pro Forma Balance Sheet
Year 1

Year 2

Year 3

Current Assets
Cash
Inventory
Other Current Assets
Total Current Assets

$350,350
$80,000
$0
$430,350

$465,519
$219,375
$0
$684,894

$576,561
$318,699
$0
$895,260

Long-term Assets
Long-term Assets
Accumulated Depreciation
Total Long-term Assets
Total Assets

$0
$0
$0
$430,350

$0
$0
$0
$684,894

$0
$0
$0
$895,260

Liabilities and Capital

Year 1

Year 2

Year 3

Current Liabilities
Accounts Payable
Current Borrowing
Other Current Liabilities
Subtotal Current Liabilities

$4,350
$0
$0
$4,350

$69,894
$0
$0
$69,894

$91,260
$0
$0
$91,260

Long-term Liabilities
Total Liabilities

$0
$4,350

$0
$69,894

$0
$91,260

Paid-in Capital
Retained Earnings
Earnings
Total Capital
Total Liabilities and Capital

$365,000
($65,000)
$126,000
$426,000
$430,350

$365,000
$61,000
$189,000
$615,000
$684,894

$365,000
$250,000
$189,000
$804,000
$895,260

Net Worth

$426,000

$615,000

$804,000

Assets

7.7 Business Ratios

Page 17

ASCLEP PHARMA
Table: Ratios
Ratio Analysis
Year 1
n.a.

Year 2
50.00%

Year 3
33.33%

Industry Profile
0.00%

18.59%
0.00%
100.00%
0.00%
100.00%

32.03%
0.00%
100.00%
0.00%
100.00%

35.60%
0.00%
100.00%
0.00%
100.00%

0.00%
100.00%
100.00%
0.00%
100.00%

1.01%
0.00%
1.01%
98.99%

10.21%
0.00%
10.21%
89.79%

10.19%
0.00%
10.19%
89.81%

0.00%
0.00%
0.00%
100.00%

100.00%
30.00%
9.00%
0.00%
30.00%

100.00%
30.00%
9.00%
0.00%
30.00%

100.00%
22.50%
6.75%
0.00%
22.50%

100.00%
0.00%
0.00%
0.00%
0.00%

Main Ratios
Current
Quick
Total Debt to Total Assets
Pre-tax Return on Net Worth
Pre-tax Return on Assets

98.93
80.54
1.01%
42.25%
41.83%

9.80
6.66
10.21%
43.90%
39.42%

9.81
6.32
10.19%
33.58%
30.16%

0.00
0.00
0.00%
0.00%
0.00%

Additional Ratios
Net Profit Margin
Return on Equity

Year 1
21.00%
29.58%

Year 2
21.00%
30.73%

Year 3
15.75%
23.51%

n.a
n.a

4.31
81.38
27
1.39

4.21
12.17
16
1.31

3.46
12.17
26
1.34

n.a
n.a
n.a
n.a

0.01
1.00

0.11
1.00

0.11
1.00

n.a
n.a

$426,000
0.00

$615,000
0.00

$804,000
0.00

n.a
n.a

0.72
1%
80.54
1.41
0.00

0.76
10%
6.66
1.46
0.00

0.75
10%
6.32
1.49
0.00

n.a
n.a
n.a
n.a
n.a

Sales Growth
Percent of Total Assets
Inventory
Other Current Assets
Total Current Assets
Long-term Assets
Total Assets
Current Liabilities
Long-term Liabilities
Total Liabilities
Net Worth
Percent of Sales
Sales
Gross Margin
Selling, General & Administrative Expenses
Advertising Expenses
Profit Before Interest and Taxes

Activity Ratios
Inventory Turnover
Accounts Payable Turnover
Payment Days
Total Asset Turnover
Debt Ratios
Debt to Net Worth
Current Liab. to Liab.
Liquidity Ratios
Net Working Capital
Interest Coverage
Additional Ratios
Assets to Sales
Current Debt/Total Assets
Acid Test
Sales/Net Worth
Dividend Payout

Page 18

Appendix
Table: Sales Forecast
Sales Forecast
Month 1

Month 2

Month 3

Month 4

Month 5

Month 6

Month 7

Month 8

Month 9

Month 10

Month 11

Month 12

Sales
Medicines
Surgical Instruments
Total Sales

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

$25,000
$25,000
$50,000

Direct Cost of Sales

Cost of Goods Medicines
Cost of Goods Surgical Supplies
Transportation Costs
Subtotal Direct Cost of Sales

Month 1
$15,000
$15,000
$5,000
$35,000

Month 2
$15,000
$15,000
$5,000
$35,000

Month 3
$15,000
$15,000
$5,000
$35,000

Month 4
$15,000
$15,000
$5,000
$35,000

Month 5
$15,000
$15,000
$5,000
$35,000

Month 6
$15,000
$15,000
$5,000
$35,000

Month 7
$15,000
$15,000
$5,000
$35,000

Month 8
$15,000
$15,000
$5,000
$35,000

Month 9
$15,000
$15,000
$5,000
$35,000

Month 10
$15,000
$15,000
$5,000
$35,000

Month 11
$15,000
$15,000
$5,000
$35,000

Month 12
$15,000
$15,000
$5,000
$35,000

Page 1

Appendix
Table: Personnel
Personnel Plan
HR Department
Finanace Department
Marketing Department
Total People
Total Payroll

Month 1
$0
$0
$0
0

Month 2
$0
$0
$0
0

Month 3
$0
$0
$0
0

Month 4
$0
$0
$0
0

Month 5
$0
$0
$0
0

Month 6
$0
$0
$0
0

Month 7
$0
$0
$0
0

Month 8
$0
$0
$0
0

Month 9
$0
$0
$0
0

Month 10
$0
$0
$0
0

Month 11
$0
$0
$0
0

Month 12
$0
$0
$0
0

$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

Page 2

Appendix
Table: Profit and Loss
Pro Forma Profit and Loss
Sales
Direct Cost of Sales
Other Costs of Sales
Total Cost of Sales

Month 1
$50,000
$35,000
$0
$35,000

Month 2
$50,000
$35,000
$0
$35,000

Month 3
$50,000
$35,000
$0
$35,000

Month 4
$50,000
$35,000
$0
$35,000

Month 5
$50,000
$35,000
$0
$35,000

Month 6
$50,000
$35,000
$0
$35,000

Month 7
$50,000
$35,000
$0
$35,000

Month 8
$50,000
$35,000
$0
$35,000

Month 9
$50,000
$35,000
$0
$35,000

Month 10
$50,000
$35,000
$0
$35,000

Month 11
$50,000
$35,000
$0
$35,000

Month 12
$50,000
$35,000
$0
$35,000

Gross Margin
Gross Margin %

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$15,000
30.00%

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0
$0
$0
$0
$0
$0
$0
$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

$0

Profit Before Interest and Taxes

EBITDA
Interest Expense
Taxes Incurred

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

$15,000
$15,000
$0
$4,500

Net Profit
Net Profit/Sales

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

$10,500
21.00%

Expenses
Payroll
Marketing/Promotion
Depreciation
Rent
Utilities
Insurance
Payroll Taxes
Other
Total Operating Expenses

15%

Page 3

Appendix
Table: Cash Flow
Pro Forma Cash Flow
Month 1

Month 2

Month 3

Month 4

Month 5

Month 6

Month 7

Month 8

Month 9

Month 10

Month 11

Month 12

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$50,000
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

$0
$0
$0
$0
$0
$0
$0
$50,000

Month 1

Month 2

Month 3

Month 4

Month 5

Month 6

Month 7

Month 8

Month 9

Month 10

Month 11

Month 12

Expenditures from Operations

Cash Spending
Bill Payments
Subtotal Spent on Operations

$0
$150
$150

$0
$4,500
$4,500

$0
$4,500
$4,500

$0
$4,500
$4,500

$0
$7,833
$7,833

$0
$101,167
$101,167

$0
$4,500
$4,500

$0
$7,833
$7,833

$0
$101,167
$101,167

$0
$4,500
$4,500

$0
$7,833
$7,833

$0
$101,167
$101,167

Additional Cash Spent

Sales Tax, VAT, HST/GST Paid Out
Principal Repayment of Current Borrowing
Other Liabilities Principal Repayment
Long-term Liabilities Principal Repayment
Purchase Other Current Assets
Purchase Long-term Assets
Dividends
Subtotal Cash Spent

$0
$0
$0
$0
$0
$0
$0
$150

$0
$0
$0
$0
$0
$0
$0
$4,500

$0
$0
$0
$0
$0
$0
$0
$4,500

$0
$0
$0
$0
$0
$0
$0
$4,500

$0
$0
$0
$0
$0
$0
$0
$7,833

$0
$0
$0
$0
$0
$0
$0
$101,167

$0
$0
$0
$0
$0
$0
$0
$4,500

$0
$0
$0
$0
$0
$0
$0
$7,833

$0
$0
$0
$0
$0
$0
$0
$101,167

$0
$0
$0
$0
$0
$0
$0
$4,500

$0
$0
$0
$0
$0
$0
$0
$7,833

$0
$0
$0
$0
$0
$0
$0
$101,167

$49,850
$149,850

$45,500
$195,350

$45,500
$240,850

$45,500
$286,350

$42,167
$328,517

($51,167)
$277,350

$45,500
$322,850

$42,167
$365,017

($51,167)
$313,850

$45,500
$359,350

$42,167
$401,517

($51,167)
$350,350

Cash Received
Cash from Operations
Cash Sales
Subtotal Cash from Operations
Additional Cash Received
Sales Tax, VAT, HST/GST Received
New Current Borrowing
New Other Liabilities (interest-free)
New Long-term Liabilities
Sales of Other Current Assets
Sales of Long-term Assets
New Investment Received
Subtotal Cash Received
Expenditures

Net Cash Flow

Cash Balance

0.00%

Page 4

Appendix
Table: Balance Sheet
Pro Forma Balance Sheet
Assets

Month 1

Month 2

Month 3

Month 4

Month 5

Month 6

Month 7

Month 8

Month 9

Month 10

Month 11

Month 12

Starting Balances

Current Assets
Cash
Inventory
Other Current Assets
Total Current Assets

$100,000
$200,000
$0
$300,000

$149,850
$165,000
$0
$314,850

$195,350
$130,000
$0
$325,350

$240,850
$95,000
$0
$335,850

$286,350
$60,000
$0
$346,350

$328,517
$125,000
$0
$453,517

$277,350
$90,000
$0
$367,350

$322,850
$55,000
$0
$377,850

$365,017
$120,000
$0
$485,017

$313,850
$85,000
$0
$398,850

$359,350
$50,000
$0
$409,350

$401,517
$115,000
$0
$516,517

$350,350
$80,000
$0
$430,350

Long-term Assets
Long-term Assets
Accumulated Depreciation
Total Long-term Assets
Total Assets

$0
$0
$0
$300,000

$0
$0
$0
$314,850

$0
$0
$0
$325,350

$0
$0
$0
$335,850

$0
$0
$0
$346,350

$0
$0
$0
$453,517

$0
$0
$0
$367,350

$0
$0
$0
$377,850

$0
$0
$0
$485,017

$0
$0
$0
$398,850

$0
$0
$0
$409,350

$0
$0
$0
$516,517

$0
$0
$0
$430,350

Month 1

Month 2

Month 3

Month 4

Month 5

Month 6

Month 7

Month 8

Month 9

Month 10

Month 11

Month 12

Liabilities and Capital

Current Liabilities
Accounts Payable
Current Borrowing
Other Current Liabilities
Subtotal Current Liabilities

$0
$0
$0
$0

$4,350
$0
$0
$4,350

$4,350
$0
$0
$4,350

$4,350
$0
$0
$4,350

$4,350
$0
$0
$4,350

$101,017
$0
$0
$101,017

$4,350
$0
$0
$4,350

$4,350
$0
$0
$4,350

$101,017
$0
$0
$101,017

$4,350
$0
$0
$4,350

$4,350
$0
$0
$4,350

$101,017
$0
$0
$101,017

$4,350
$0
$0
$4,350

Long-term Liabilities
Total Liabilities

$0
$0

$0
$4,350

$0
$4,350

$0
$4,350

$0
$4,350

$0
$101,017

$0
$4,350

$0
$4,350

$0
$101,017

$0
$4,350

$0
$4,350

$0
$101,017

$0
$4,350

Paid-in Capital
Retained Earnings
Earnings
Total Capital
Total Liabilities and Capital

$365,000
($65,000)
$0
$300,000
$300,000

$365,000
($65,000)
$10,500
$310,500
$314,850

$365,000
($65,000)
$21,000
$321,000
$325,350

$365,000
($65,000)
$31,500
$331,500
$335,850

$365,000
($65,000)
$42,000
$342,000
$346,350

$365,000
($65,000)
$52,500
$352,500
$453,517

$365,000
($65,000)
$63,000
$363,000
$367,350

$365,000
($65,000)
$73,500
$373,500
$377,850

$365,000
($65,000)
$84,000
$384,000
$485,017

$365,000
($65,000)
$94,500
$394,500
$398,850

$365,000
($65,000)
$105,000
$405,000
$409,350

$365,000
($65,000)
$115,500
$415,500
$516,517

$365,000
($65,000)
$126,000
$426,000
$430,350

Net Worth

$300,000

$310,500

$321,000

$331,500

$342,000

$352,500

$363,000

$373,500

$384,000

$394,500

$405,000

$415,500

$426,000

Page 5